Immunohistochemical identification of complement peptide C5a receptor 1 (C5aR1) in non-neoplastic and neoplastic human tissues

Benjamin Nürge¹, Alan Lennart Schulz¹, Daniel Kaemmerer², Jörg Sänger³, Katja Evert⁴,⁵, Stefan Schulz¹, Amelie Lupp¹

¹ Institute of Pharmacology and Toxicology, Jena University Hospital, Jena, Germany, ² Department of General and Visceral Surgery, Zentralklinik Bad Berka, Bad Berka, Germany, ³ Laboratory of Pathology and Cytology Bad Berka, Bad Berka, Germany, ⁴ Department of Pathology, University of Regensburg, Regensburg, Germany, ⁵ Institute of Pathology, University Medicine of Greifswald, Greifswald, Germany

* Amelie.Lupp@med.uni-jena.de

Abstract

The complement component C5a and its receptor C5aR1 are involved in the development of numerous inflammatory diseases. In addition to immune cells, C5aR1 is expressed in neoplastic cells of multiple tumour entities, where C5aR1 is associated with a higher proliferation rate, advanced tumour stage, and poor patient outcomes. The aim of the present study was to obtain a broad expression profile of C5aR1 in human non-neoplastic and neoplastic tissues, especially in tumour entities not investigated in this respect so far. For this purpose, we generated a novel polyclonal rabbit antibody, (5227), against the carboxy-terminal tail of C5aR1. The antibody was initially characterised in Western blot analyses and immunocytochemistry using transfected human embryonic kidney (HEK) 293 cells. It was then applied to a large series of formalin-fixed, paraffin-embedded non-neoplastic and neoplastic human tissue samples. C5aR1 was strongly expressed by different types of immune cells in the majority of tissue samples investigated. C5aR1 was also highly expressed in the vast majority of the 32 tumour entities investigated, where a hitherto unappreciated high prevalence of the receptor was detected in thyroid carcinomas, small-cell lung cancer, gastrointestinal stromal tumours, and endometrial carcinomas. In addition to confirming published findings, we found noticeable C5aR1 expression in many tumour entities for the first time. Here, it may serve as an interesting target for future therapies.
Introduction

The complement system has important functions in innate immunity. These functions include opsonisation and phagocytosis, inflammation through recruitment of macrophages and neutrophils to sites of infection, and assembly of the membrane attack complex (MAC). Proteases in the complement system circulate as inactive precursors, which are sequentially activated by specific triggers, such as antigen-antibody complexes, foreign material, pathogens, damaged cells, or antigens, or by spontaneous hydrolysis of the complement component C3. Biochemical pathways regulating protease activation include the classical complement pathway, the alternative complement pathway, and the lectin pathway [1, 2]. One of the most important components of the complement cascade is C5a, which binds to the receptors C5aR1 (CD88) and C5aR2 (C5L2, GPR77). Activated C5aR1, a membrane-bound G-protein coupled receptor (GPCR), increases migration and adhesion of neutrophils and monocytes to vessel walls, resulting in the recruitment of immune cells to sites of infection or antigen-presenting cells to lymph nodes. Furthermore, activation of C5aR1 by C5a causes mast cell degranulation, cytokine release, and oxidative burst of immune cells [3–5]. The function of C5aR2, which is uncoupled from G proteins, remains controversial. As a decoy receptor for C5a, C5aR2 may prevent C5aR1-mediated immune cell activation. However, C5aR2 may also induce G-protein-independent signalling pathways, promoting anti- or pro-inflammatory actions [6–8].

The C5a/C5aR1 axis is involved in multiple inflammatory diseases, including allergic asthma, rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus, psoriasis, ischemia reperfusion injury, and sepsis [9, 10]. C5aR1 expression has also been described in a number of tumours. Here, it has been demonstrated to be associated with increased proliferation, metastasis, advanced tumour stage, and poor prognosis [11, 12]. Therefore, targeting C5a or C5aR1 may represent a promising therapeutic strategy for these tumour entities [11, 12].

Against this background, the objective of the present study was to evaluate C5aR1 expression by immunohistochemistry in a broad panel of non-neoplastic and neoplastic human tissue samples from routine pathology to obtain a broad expression profile of C5aR1 in these tissues and to provide a basis for more in-depth investigations with regard to diagnostic or therapeutic interventions also in tumour entities not investigated in this respect so far. Due to the extent of the study, we decided to generate and validate our own C5aR1 antibody which should be well-suited on one hand for immunohistochemical investigations on formalin-fixed, paraffin-embedded routine pathology samples but also for basic research in future projects on human cell lines and tissues using immunocytochemistry and Western blot analyses.

Materials and methods

Antibody

A rabbit polyclonal antibody, (5227), directed against the carboxy-terminal tail of human C5aR1 was generated in collaboration with and obtained from Thermo Fisher Scientific (Waltham, MA, USA). The identity of the peptide used for immunisation of rabbits was Cys-ESKSFTRSTVDTMAQKTQAV, which corresponds to residues 331–350 of human C5aR1. This sequence is unique to human C5aR1 and the antibody does not cross-react with rat or mouse C5aR1 due to dissimilarities in carboxyl-terminal amino acid sequences (Fig 1).

Western blot analysis

Human embryonic 293 (HEK-293) cells were obtained from the German Collection of Microorganisms and Cell Cultures GmbH (ACC 305; Deutsche Sammlung von Mikroorganismen
human: 331 ESKSFTRSTVDMAQKTQAV 350

mouse: 331 RDSKTFTPSTTDSTRKSQA 350

rat: 331 GRDSKFTRSTMDTSTQKSQ 350

Fig 1. Carboxy-terminal sequence of human, mouse, and rat C5aR1. Differences in amino acid sequences of rat and mouse C5aR1 in comparison with the human receptor are marked in red.

und Zellkulturen; DSMZ, Braunschweig, Germany) and were cultured up to the 10th passage at most, to avoid genetic drift. Cell cultures were checked monthly by PCR for mycoplasma contamination. Cells were cultured at 37°C and 5% CO2 in Dulbecco’s modified Eagle’s medium (DMEM), supplemented with 10% fetal bovine serum, 2 mM L-glutamine and 100 U/ml penicillin/streptomycin. HEK293 cells were stably transfected with human C5aR1 or human C5aR2 using TurboFect (Thermo Fisher Scientific, Waltham, MA, USA). Stably transfected cells were selected in medium supplemented with 400 μg/ml geneticin (Thermo Fisher Scientific, Waltham, MA, USA). For Western blot analysis, cells were seeded onto poly-L-lysine-coated 60-mm dishes and grown to 80% confluence. Cells were lysed in detergent buffer [20 mM HEPES (pH 7.4), 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 10% glycerol, 0.1% SDS, 0.2 mM phenylmethylsulfonylfluoride, 10 mg/ml leupeptin, 1 mg/ml pepstatin A, 1 mg/ml aprotinin, and 10 mg/ml bacitracin]. C5aR1 and C5aR2 were enriched using wheat germ lectin agarose beads. Samples were subjected to 7.5% SDS-polyacrylamide gel electrophoresis and immunoblotted onto polyvinylidene fluoride (PVDF) membranes. Blots were incubated with rabbit polyclonal anti-C5aR1 antibody {5227} or rabbit polyclonal anti-C5aR2 antibody {5236} at a dilution of 1:500 followed by peroxidase-conjugated secondary goat anti-rabbit antibody at a 1:5,000 dilution (Santa Cruz Biotechnology, Dallas, TX, USA) and enhanced chemiluminescence detection (SuperSignal West Dura Extended Duration Substrate, Thermo Fisher Scientific, Waltham, MA, USA).

Immunocytochemistry

HEK-293 cells stably transfected with human C5aR1 or human C5aR2 were grown on coverslips overnight. Cells were then fixed with 4% paraformaldehyde and 0.2% picric acid in phosphate buffer (pH 6.9) for 20 min at room temperature, washed with phosphate buffer, and incubated with rabbit polyclonal anti-C5aR1 antibody {5227} or rabbit polyclonal anti-C5aR2 antibody {5236} (1:500) at room temperature for 2 h, followed by an Alexa Fluor 488-conjugated secondary goat anti-rabbit antibody (Invitrogen, Karlsruhe, Germany; dilution: 1:5,000) overnight at 4°C. Samples were mounted and examined using a Zeiss LSM 510 META laser-scanning confocal microscope (Jena, Germany).

Immunohistochemical evaluation of C5aR1 expression in non-neoplastic and neoplastic human tissues

Tissue specimens. C5aR1 expression was evaluated in 330 formalin-fixed and paraffin-embedded human tissue samples, consisting of 257 tumour specimens from 32 different tumour entities (n = 1–10 each; Table 1) and 73 tumour-free specimens from lung, heart, liver, gut, pancreas, kidney, spleen, tonsil, thymus, lymph node, placenta, and bone (n = 6–15 each).
Many of the tumour specimens contained adjacent non-malignant tissues, which were also analysed. Staining patterns were compared to those in the non-malignant tissues surrounding tumours. Completely anonymised samples were obtained from the Department of Pathology at Ernst-Moritz-Arndt-University (Greifswald, Germany) and the Laboratory of Pathology and Cytology Bad Berka (Bad Berka, Germany). Permission was obtained from the local ethics committees (Ethikkommission an der Universität Greifswald; Ethikkommission der Landesärztekammer Thüringen) to access material from the pathology archives for the present study. For this type of study on anonymized human samples being archived for more than 10 years and which does not include clinical data, according to the local ethics committees formal consent was not required.

Table 1. Presence of C5aR1 in the tumour cells of different tumour entities.

| Tumour type                                    | C5aR1-positive tumours, n | Immunoreactive score (IRS) |
|------------------------------------------------|--------------------------|---------------------------|
| (total number of cases)                        |                          | mean | min | max |
| Glioblastoma (8)                               | 4                        | 3.44 | 0   | 9   |
| Meningioma (6)                                 | 5                        | 4.17 | 0   | 6   |
| Pituitary adenoma (10)                         | 5                        | 2.60 | 0   | 6   |
| Thyroid carcinoma (37)                         | 36                       | 5.76 | 2   | 10  |
| • papillary (10)                               | 10                       | 5.60 | 4   | 8   |
| • follicular (10)                              | 9                        | 4.50 | 2   | 8   |
| • medullary (9)                                | 9                        | 5.44 | 3   | 8   |
| • anaplastic (8)                               | 8                        | 7.50 | 6   | 10  |
| Lung cancer (30)                               | 15                       | 3.15 | 0   | 8   |
| • Adenocarcinoma (10)                          | 5                        | 2.95 | 0   | 6   |
| • Squamous cell carcinoma (10)                 | 1                        | 1.50 | 0   | 4.5 |
| • Small-cell lung cancer (10)                  | 9                        | 5.00 | 2   | 8   |
| Breast carcinoma (9)                           | 2                        | 1.22 | 0   | 4   |
| Gastric adenocarcinoma (10)                    | 8                        | 4.40 | 0   | 6   |
| Hepatocellular carcinoma (10)                  | 10                       | 6.20 | 4   | 10  |
| Cholangiocellular carcinoma (9)                | 8                        | 6.77 | 2   | 12  |
| Pancreatic adenocarcinoma (10)                 | 9                        | 4.55 | 0   | 12  |
| Pancreatic neuroendocrine tumour (10)          | 6                        | 2.05 | 0   | 4.5 |
| Colon carcinoma (9)                            | 5                        | 3.06 | 1.5 | 6   |
| Gastrointestinal stromal tumour (9)            | 9                        | 8.44 | 4   | 12  |
| Pheochromocytoma (6)                           | 0                        | 0    | 0   | 0   |
| Renal clear cell carcinoma (7)                 | 7                        | 6.07 | 4.5 | 8   |
| Prostate adenocarcinoma (10)                   | 1                        | 1.60 | 0   | 6   |
| Testicular cancer (10)                         | 3                        | 1.40 | 0   | 4   |
| Ovarian cancer (9)                             | 9                        | 7.89 | 3   | 12  |
| Endometrial cancer (10)                        | 10                       | 5.60 | 4   | 8   |
| Cervical cancer (9)                            | 8                        | 4.06 | 2   | 6   |
| Melanoma (5)                                   | 2                        | 2.00 | 1   | 4   |
| Lymphoma (10)                                  | 8                        | 3.70 | 2   | 6   |
| Sarcoma (14)                                   | 3                        | 1.36 | 0   | 6   |
| • Leiomyosarcoma (4)                           | 0                        | 0.50 | 0   | 2   |
| • Rhabdomyosarcoma (3)                         | 2                        | 3.00 | 0   | 6   |
| • Pleomorphic sarcoma (2)                      | 0                        | 1.00 | 0   | 2   |
| • Liposarcoma (4)                              | 0                        | 0    | 0   | 0   |
| • Angiosarcoma (1)                             | 1                        | 6.00 | 6   | 6   |

https://doi.org/10.1371/journal.pone.0246939.t001
Immunohistochemistry. From the paraffin blocks, 4-μm sections were prepared and floated onto positively charged slides. Immunostaining was performed by an indirect peroxidase-labelling method as previously described [13]. Briefly, sections were dewaxed, micro-waved in 10 mM citric acid (pH 6.0) for 16 min at 600 W, and incubated with {5227} (dilution: 1:500) overnight at 4˚C. Detection of the primary antibody was performed using biotinylated goat anti-rabbit IgG (Vector ABC “Elite” kit; Vector Laboratories, Burlingame, CA, USA) followed by incubation with peroxidase-conjugated avidin (Vector ABC “Elite” kit; Vector Laboratories, Burlingame, CA, USA). Binding of the primary antibody was visualised using 3-amino-9-ethylcarbazole in acetate buffer (BioGenex, San Ramon, CA, USA). Sections were rinsed, counterstained with Mayer’s haematoxylin, and mounted in Vectamount mounting medium (Vector Laboratories, Burlingame, CA, USA). For immunohistochemical controls, {5227} was either omitted or adsorbed for 2 h at room temperature with 10 μg/ml of the peptide used for immunisations.

C5aR1 tumour staining was scored using the semi-quantitative Immunoreactivity Score (IRS) according to Remmele and Stegner [14]. The percentage of positive tumour cells assessed in five gradations (no positive cells (0), <10% positive cells (1), 10–50% positive cells (2), 51–80% positive cells (3), and >80% positive cells (4)) was multiplied by the staining intensity quantified in four gradations (no staining (0), mild staining (1), moderate staining (2), and strong staining (3)). Thus, IRS values ranging from 0 to 12 were obtained. Two independent, blinded investigators (BN, AL) evaluated all stained slides. Final decisions on discrepant scores were achieved by consensus.

Results

Characterisation of rabbit anti-human C5aR1 antibody {5227}

The specificity of anti-human C5aR1 antibody {5227} was first tested by Western blot analysis of transfected HEK-293 cells. The anti-C5aR1 antibody {5227} detected a broad band migrating at 45–58 kDa, corresponding to the expected molecular weight range of the variably glycosylated receptor, in cells stably expressing C5aR1 but not in cells expressing C5aR2 (Fig 2A, left panel). Conversely, the rabbit polyclonal anti-human C5aR2 antibody {5236} detected a broad band migrating at 45–56 kDa in cells expressing C5aR2 but not in cells expressing C5aR1 (Fig 2A, right panel). The anti-C5aR1 antibody {5227} was further characterised using immunofluorescent staining of transfected cells. The anti-C5aR1 antibody {5227} demonstrated prominent immunofluorescence localisation at the plasma membrane in C5aR1-expressing cells but not in C5aR2-expressing cells (Fig 2B). On the other hand, the anti-C5aR2 antibody {5236} revealed punctate cytoplasmic immunofluorescence only in C5aR2-expressing and not in C5aR1-expressing cells (Fig 2B). This punctate cytoplasmic immunofluorescence most likely reflects localization of C5aR2 in endosomal vesicles, which would be in line with the function of C5aR2 as decoy receptor.

Immunohistochemical detection of C5aR1 expression in non-neoplastic and neoplastic human tissues

The rabbit polyclonal anti-C5aR1 antibody {5227} was then subjected to immunohistochemical staining of a large panel of non-neoplastic and neoplastic human tissues. In all positive cases, the immunostaining was confined to the plasma membrane and to the cytoplasm of the cells. A set of both non-neoplastic and neoplastic tissues showing positive staining for C5aR1 was also incubated with {5227} pre-adsorbed with the immunising peptide, which, in all cases,
Fig 2. Analysis of the specificity of anti-human rabbit polyclonal antibody (5227). (A) Western blot analysis of whole cell preparations from stably C5aR1- or C5aR2-transfected HEK-293 cells. Receptors were enriched using wheat germ lectin agarose beads. Samples were separated on 7.5% SDS-polyacrylamide gels and blotted onto PVDF membranes. Membranes were then incubated with anti-human C5aR1 antibody (5227) or anti-human C5aR2 antibody (5236), and blots were developed using enhanced chemiluminescence. Ordinate, migration of protein molecular weight markers (kDa). Note that (5227) and (5236) selectively detected only the respective targeted receptor and did not cross-react with the other receptor or other membrane proteins. (B) Immunocytochemistry of stably C5aR1- or C5aR2-transfected HEK-293 cells. Cells were fixed and immunofluorescently stained with anti-human
led to complete abolishment of the immunosignal (see insets in Figs 4B, 5A, 5C-5E, 6A, 6B, 6D, and 6E).

Various types of strongly C5aR1-positive immune cells were detected in nearly all non-neoplastic and neoplastic tissue samples. Based on localisation and morphology, these cells most likely represent monocytes, macrophages, granulocytes, dendritic cells, and mast cells. In addition to other immune cells, alveolar macrophages in the lung displayed strong C5aR1 expression (Fig 3A, 3B, 3D and 3E). C5aR1 staining was also noted in the epithelia of the airways. The heart was mostly negative except for immune cells within the lumen of vessels (Fig 3G, arrows). Whereas in the exocrine pancreas no or only faint staining was observed, a few cells at the outer edge of the pancreatic islets showed strong C5aR1 expression (Fig 3H, arrows). Kupffer cells in the liver showed strong C5aR1 immunostaining (Fig 3I, arrows). Bile duct epithelia were also C5aR1-positive. Seven of the 15 liver tissue samples showed C5aR1 expression in the hepatocytes, primarily those in periportal areas (Fig 3C and 3F). In the other eight of the liver tissue samples, however, hepatocytes were largely negative (Fig 3I). In the kidneys, C5aR1 expression was confined to the epithelial cells of the proximal tubules (Fig 4A). C5aR1 positivity was also observed in the epithelia of the duodenum, jejunum, ileum, and colon and in syncytiotrophoblasts of placenta (not shown). C5aR1 was detected in distinct cell populations of the red pulp of the spleen, most probably representing granulocytes and macrophages (Fig 4B and 4E), whereas the thymus (Fig 4D) and the white pulp of the spleen were largely negative. Similarly, the tonsils and lymph nodes were largely negative except for dendritic cells in the germ centres of secondary follicles and lymphocytes and macrophages in reactive lymph follicles (e.g., in the vicinity of tumour cells of tumour-bearing lymph nodes) (Fig 6C, arrowheads). Finally, positive immunostaining was detected in distinct cell populations within the bone marrow (Fig 4C and 4F), whereas osteoblasts, osteocytes, and osteoclasts in bone tissue were negative.

The patterns of C5aR1 distribution in human tumour samples are summarised in Table 1. Representative examples of immunostaining are shown in Figs 5 and 6. Also here, both membranous and cytoplasmic staining of cells was observed. Notably, C5aR1 expression in the different tumour entities displayed substantial inter-individual variability. Overall, significant C5aR1 expression was observed in the majority of the 32 tumour entities investigated. Only a few tumour entities, such as pituitary adenomas, adenocarcinomas and squamous cell carcinomas of the lung, breast carcinomas, pancreatic neuroendocrine tumours, pheochromocytomas, prostate adenocarcinomas, testicular carcinomas, melanomas, and sarcomas were largely negative. By contrast, pronounced C5aR1 expression in a higher number of tumour samples was observed in all types of thyroid carcinomas, small-cell lung cancer, hepatocellular and cholangiocellular carcinomas, pancreatic adenocarcinomas, gastrointestinal stromal tumours, renal clear cell carcinomas and ovarian and endometrial cancer.

Discussion

Characterisation of rabbit anti-human C5aR1 antibody {5227}

The primary objective of the present study was to obtain a broad expression profile of C5aR1 in human non-neoplastic and neoplastic tissues and to provide a basis for future more in-
depth investigations with regard to diagnostic or therapeutic interventions also in tumour entities not investigated in this respect so far. Due to the extent of the study, we decided to generate and thoroughly characterise our own C5aR1 antibody which should be well-suited on one hand for immunohistochemical investigations on formalin-fixed, paraffin-embedded routine pathology samples but also for basic research on human cell lines and tissues using immunocytochemistry and Western blot analyses.

We were able to demonstrate that our novel anti-C5aR1 antibody [5227] specifically detects its target and does not cross-react with other proteins. First, in Western blot analyses, the anti-
C5aR1 antibody selectively detected its cognate receptor at the expected molecular weight of the glycosylated receptor in crude extracts from C5aR1-transfected HEK-293 [15, 16] but not in extracts from C5aR2-transfected cells. Second, the antibody revealed membranous staining of C5aR1-transfected HEK-293 cells, whereas no immunostaining was observed in C5aR2-transfected cells. Third, the novel anti-C5aR1 antibody {5227} showed highly efficient membranous and cytoplasmic staining of distinct cell populations known to express C5aR1 within formalin-fixed, paraffin-embedded human tissue samples. This staining was completely abolished after pre-adsorption of the antibody with its immunising peptide.

Immunohistochemical detection of C5aR1 expression in non-neoplastic human tissues

C5aR1 is known to be expressed in distinct immune cell populations, such as monocytes, macrophages, monocyte-derived dendritic cells, eosinophilic and neutrophilic granulocytes, and mast cells [17–20]. The results of the current study agree with these findings. Based on our results showing negative staining in lymph nodes, the white pulp of the spleen, the tonsils, and thymus glands, resting B and T lymphocytes do not express C5aR1, which also corresponds well with previous reports [17–20]. As evident from the cervical cancer lymph node metastasis depicted in Fig 6C, C5aR1 may, however, be present in memory B cells and/or plasma cells [21].
In addition to the above-mentioned immune cells [20, 22–25], alveolar macrophages and bronchial epithelial cells have been shown to be C5aR1-positive [16, 22], which is consistent with our results. An increased concentration of C5a and an elevated amount of neutrophilic and eosinophilic granulocytes has been detected in the bronchoalveolar lavage fluid of asthma patients [26]. Furthermore, anti-C5aR1 treatment reduced the amount of neutrophilic and eosinophilic granulocytes in the bronchoalveolar lavage fluid of a mouse model of allergic asthma [27]. Therefore, C5a and C5aR1 may be interesting targets for treating asthma [9, 28].

In seven of the 15 liver samples, pronounced C5aR1 expression was detected in a distinct hepatocyte subpopulation in the periportal areas of the liver lobules. By contrast, the remaining eight liver samples were largely negative, except for infiltrating immune cells, Kupffer cells, and bile duct epithelia. These results agree with literature data showing that C5aR1 is not expressed in normal rat or human hepatocytes [29–32] in contrast to Kupffer cells [31, 32] and bile duct epithelia [11]. Under inflammatory conditions, however, C5aR1 expression can be distinctly induced in hepatocytes of mice, rats, and humans [22, 31, 32]. Upregulation of C5aR1 expression has also been shown to occur in the regenerating liver of rats after partial hepatectomy [33]. It is therefore likely that inflammatory and/or regenerative processes were present in the positively stained samples of the current study.

Pancreatic tissues showed only a few C5aR1-positive cells, which were located on the outer edge of the islets. These cells may represent glucagon-, somatostatin-, or pancreatic polypeptide-producing cells. The insulin-producing beta cells, however, which represent the majority of pancreatic islets, were C5aR1-negative.

Fig 5. Immunohistochemical detection of C5aR1 localization in human tumor entities (I). Immunohistochemical staining (red-brown colour), counterstaining with haematoxylin. Scale bar: 50 μm (A–F). Insets in (A, C, D, E): for adsorption control, the anti-C5aR1 antibody (5227) was incubated with 10 μg/ml of the peptide used for immunisations. Lung SQCC: squamous cell carcinoma of the lung; PTC: papillary thyroid carcinoma; ATC: anaplastic thyroid carcinoma; CCC: cholangiocellular carcinoma.

https://doi.org/10.1371/journal.pone.0246939.g005
of islet cells, were negative. Similar, low C5aR1 mRNA expression in human and mouse pancreatic islets has been described [34]. The authors of that study also demonstrated that treatment of islet cells in vitro with C5a or a C5aR1 agonist increases intracellular calcium and ATP concentrations, potentiates glucose-induced insulin secretion, and protects cells from apoptosis, whereas treatment with a C5aR1 antagonist caused a decrease in insulin secretion. Therefore the authors suggested that C5aR1 is expressed on beta cells, and mild inflammation may have a positive impact on glucose homeostasis via a direct effect on these cells [34]. In an animal model of diet-induced obesity, however, no difference in pancreatic islet morphology and beta cell mass was observed between wild-type and C5aR1-knockout animals, although C5aR1-deficient mice exhibited improved insulin sensitivity and fewer macrophages, particularly pro-inflammatory M1 macrophages, in the adipose tissue [35]. Thus, further investigation about the nature of C5aR1-expressing islet cells is needed.

C5aR1 expression was also observed in proximal renal tubule cells, which is consistent with previous reports [11, 29, 30, 36].

Results regarding C5aR1 expression in the non-neoplastic gut are controversial. Similar to our results, one report showed C5aR1 in epithelia of the small bowel and colon of mouse and pavian [22]. However, other studies did not find C5aR1 expression in human samples [11, 37]. Further investigations are necessary to clarify these discrepancies. Distinct C5aR1 expression was also observed in the syncytiotrophoblasts of the placenta, which, again, corresponds well

---

Fig 6. Immunohistochemical detection of C5aR1 localisation in human tumour entities (II). Immunohistochemical staining (red-brown colour), counterstaining with haematoxylin. Scale bar: 50 μm (A-F). Insets in (A, B, D, E): for adsorption control, the anti-C5aR1 antibody [5227] was incubated with 10 μg/ml of the peptide used for immunisations. Arrow in (C): tumour cells (lymph node metastasis of a cervical carcinoma); arrowheads in (C): lymph follicle. MTS: lymph node metastasis; PSRC: pleomorphic sarcoma.

https://doi.org/10.1371/journal.pone.0246939.g006
with recent findings in the literature [38]. Here, the C5α –C5αR1 axis has been related to different pathologies, such as placental dysfunction, pre-eclampsia, intrauterine growth restriction, and spontaneous abortion [38–40]. In bone marrow, C5αR1 expression has been demonstrated on mesenchymal stem cells and myeloid but not lymphatic hematopoietic precursor cells [17, 41], which is consistent with our findings. Here, the C5α –C5αR1 axis seems to be involved in the mobilization of stem cells into the blood and in the recruitment of these cells to damaged tissues [41, 42].

Immunohistochemical detection of C5αR1 expression in neoplastic human tissues

In the present study, 32 different tumour entities were evaluated for C5αR1 expression. In the majority of tumour types, a high percentage of cases showed significant C5αR1 expression. For many entities, literature data could be confirmed, e.g., for adenocarcinomas and squamous cell carcinomas of the lung [43–45], breast cancer [11, 46], gastric adenocarcinomas [11, 47–49], hepatocellular and cholangiocellular carcinomas [11, 50], pancreatic adenocarcinomas [11], colon carcinomas [11], renal clear cell cancer [11, 51], prostate adenocarcinomas [11], cervical cancer [52], and ovarian cancer [53]. In some studies, the presence of the C5αR1 was associated with a higher proliferation rate, metastatic disease, advanced tumour stage, and poor patient outcomes [43, 44, 46–51, 53]. Furthermore, in animal models of lung cancer, gastric cancer, or ovarian cancer, anti-C5α treatment or C5αR1 knockdown, silencing or inhibition decreased proliferation, tumour vascularisation, tumour growth, and metastatic burden [44, 49, 53, 54]. Thus, C5αR1 may represent an interesting therapeutic target for many tumour entities [12].

Among the 32 tumour entities investigated in the present study, 19 were evaluated for C5αR1 expression for the first time. These tumour types were glioblastomas, meningiomas, pituitary adenomas, papillary, follicular, medullary and anaplastic thyroid carcinomas, small cell lung cancer, gastrointestinal stromal tumours, pheochromocytomas, testicular cancer, endometrial carcinomas, melanomas, lymphomas and sarcomas, some of which are quite often diagnosed in humans. Here, thyroid carcinomas, small-cell lung cancer, gastrointestinal stromal tumours and endometrial carcinomas displayed noticeable C5αR1 expression in a high percentage of samples. Because this may be of therapeutic relevance in the future, further investigations with larger numbers of cases are warranted in these tumour entities.

Conclusions

With the help of our novel antibody, we were able to detect C5αR1 expression in a wide variety of non-neoplastic and neoplastic tissues. In addition to confirming published findings, we found noticeable C5αR1 expression in many tumour entities, such as in thyroid carcinomas, small-cell lung cancer, gastrointestinal stromal tumours and endometrial carcinomas, for the first time. Here, as well as in other strongly C5αR1-positive tumour entities, C5αR1 may serve as an interesting target for future therapies.

Supporting information

S1 Raw images.
(PDF)

Acknowledgments

The authors would like to thank Stefanie Lange for excellent technical assistance.
Author Contributions

Formal analysis: Amelie Lupp.
Investigation: Benjamin Nürge, Alan Lennart Schulz, Amelie Lupp.
Project administration: Amelie Lupp.
Resources: Daniel Kaemmerer, Jörg Sänger, Katja Evert, Stefan Schulz, Amelie Lupp.
Supervision: Amelie Lupp.
Validation: Amelie Lupp.
Visualization: Amelie Lupp.
Writing – original draft: Amelie Lupp.
Writing – review & editing: Benjamin Nürge, Daniel Kaemmerer, Jörg Sänger, Katja Evert, Stefan Schulz, Amelie Lupp.

References

1. Ehrnthaller C, Ignatius A, Gebhard F, Huber-Lang M. New insights of an old defense system: structure, function, and clinical relevance of the complement system. Mol Med. 2011; 17: 317–329. https://doi.org/10.219/molmed.2010.00149 PMID: 21046060
2. Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement system part I—molecular mechanisms of activation and regulation. Front Immunol. 2015; 6: 262. https://doi.org/10.3389/fimmu.2015.00262 PMID: 26082779
3. Monk PN, Scola AM, Madala P, Fairlie DP. Function, structure and therapeutic potential of complement C5a receptors. Br J Pharmacol. 2007; 152: 429–448. https://doi.org/10.1038/sj.bjp.0707332 PMID: 17603557
4. Klos A, Tenner AJ, Johswich KO, Ager RR, Köhl J. The role of anaphylatoxins in health and disease. Mol Immunol. 2009; 46: 2753–2766. https://doi.org/10.1016/j.molimm.2009.04.027 PMID: 19477527
5. Klos A, Wende E, Wareham KJ, Monk PN. International Union of Basic and Clinical Pharmacology. LXXXVII. Complement peptide C5a, C4a, and C3a receptors. Pharmacol Rev. 2013; 65: 500–543. https://doi.org/10.1124/pr.111.005223 PMID: 23384323
6. Scola AM, Johswich KO, Morgan BP, Klos A, Monk PN. The human complement factor receptor, C5L2, is a recycling decoy receptor. Mol Immunol. 2009; 46: 1149–1162. https://doi.org/10.1016/j.molimm.2008.11.001 PMID: 19100624
7. Bamberg CE, Mackay CR, Lee H, Zahra D, Jackson J, Lim YS, et al. 2010. The C5a receptor (C5aR) C5L2 is a modulator of C5aR-mediated signal transduction. J Biol Chem. 2010; 285: 7633–7644. https://doi.org/10.1074/jbc.M109.092106 PMID: 2004484
8. Li R, Coulthard LG, Wu MCL, Taylor SM, Woodruff TM. C5L2: a controversial receptor of complement anaphylatoxin, C5a. FASEB J. 2013; 27: 855–864. https://doi.org/10.1096/ftj.12-220509 PMID: 23239822
9. Guo RF, Ward PA. Role of C5a in inflammatory responses. Annu Rev Immunol. 2005; 23: 821–852. https://doi.org/10.1146/annurev.immunol.23.021704.115835 PMID: 15771587
10. Manthey HD, Woodruff TM, Taylor SM, Monk PN. Complement component 5a (C5a). Int J Biochem Cell Biol. 2009; 41: 2114–2117. https://doi.org/10.1016/j.biocel.2009.04.005 PMID: 19464229
11. Nitta H, Wada Y, Kawano Y, Murakami Y, Irie A, Taniguchi K, et al. Enhancement of human cancer cell motility and invasiveness by anaphylatoxin C5a via aberrantly expressed C5a receptor (CD88). Clin Cancer Res. 2013; 19: 2004–2013. https://doi.org/10.1158/1078-0432.CCR-12-1204 PMID: 23287562
12. Wang Y. Important roles of C5a and C5aR in tumor development and cancer treatment. E3S Web of Conferences. 2019;136: 06012.
13. Kaemmerer D, Sänger J, Arsenic R, D’Haese JG, Neumann J, Schmitt-Graeff A, et al. Evaluation of somatostatin, CXCR4 chemokine and endothelin A receptor expression in a large set of paragangliomas. Oncotarget. 2017; 8: 89958–89969. https://doi.org/10.18632/oncotarget.21194 PMID: 29163802
14. Remmelte W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 1987; 8: 138–140. PMID: 3303008

15. Rollins TE, Siciliano S, Kobayashi S, Cianciarulo DN, Bonilla-Argudo V, Collier K, et al. Purification of the active C5a receptor from human polymorphonuclear leukocytes as a receptor-Gi complex. Proc Natl Acad Sci USA. 1991; 88: 971–975. https://doi.org/10.1073/pnas.88.3.971 PMID: 1899485

16. Florenani AA, Heires AJ, Welniak LA, Miller-Lindholm A, Clark-Pierce L, Rennard SI, et al. Expression of C5a anaphylatoxin (CD88) on human bronchial epithelial cells: enhancement of C5a-mediated release of IL-8 upon exposure to cigarette smoke. J Immunol. 1998; 160: 5073–5081. PMID: 9950258

17. Werfel T, Oppermann M, Schulze M, Krieger G, Weber M, Götz O. Binding of fluorescein-labeled anaphylatoxin C5a to human peripheral blood, spleen, and bone marrow leukocytes. Blood. 1992; 79: 152–160. PMID: 1345807

18. Soruri A, Kim S, Kiafard Z, Zwirner J. Characterization of C5aR expression on murine myeloid and lymphoid cells by the use of a novel monoclonal antibody. Immunol Lett. 2003; 88: 47–52. https://doi.org/10.1016/s0165-2478(03)00052-x PMID: 12853161

19. Dunkelberger J, Zhou L, Miwa T, Song WC. C5aR expression in a novel GFP reporter gene knockin mouse: implications for the mechanism of action of C5aR signaling in T cell immunity. J Immunol. 2012; 188: 4032–4042. https://doi.org/10.4049/jimmunol.1103141 PMID: 22430734

20. Karsten CM, Laumonnier Y, Eurich B, Ender F, Brocker K, Roy S, et al. Monitoring and cell-specific deletion of C5aR1 using a novel floxed GFP-C5aR1 reporter knock-in mouse. J Immunol. 2015; 194: 1841–1855. https://doi.org/10.4049/jimmunol.1401401 PMID: 25589074

21. Ottonello L, Corcione A, Tortolina G, Airolidi I, Albesiano E, Favre A, et al. rC5a directs the in vivo migration of human memory and naive tonsillar B lymphocytes: implications for B cell trafficking in secondary lymphoid tissues. J Immunol. 1999; 162: 6510–6517. PMID: 10352266

22. Haviland DL, McCoy RL, Whitehead WT, Akama H, Molmenti EP, Brown A, et al. Cellular expression of the C5a anaphylatoxin receptor (C5aR): demonstration of C5aR on nonmyeloid cells of the liver and lung. J Immunol. 1995; 154: 1861–1869. PMID: 7836770

23. Oskeritzian CA, Zhao W, Min HK, Xia HZ, Pozez A, Kiev J, et al. Surface CD88 functionaly distinguishes the MC<sub>TC</sub> from the MC<sub>T</sub> type of human lung mast cell. J Allergy Clin Immunol. 2005; 115:1162–1168. https://doi.org/10.1016/j.jaci.2005.02.022 PMID: 15940129

24. Skokowa J, Ali SR, Felda O, Kumar V, Konrad S, Shushakova N, et al. Macrophages induce the inflammatory response in the pulmonary Arthus reaction through G alpha i2 activation that controls C5aR and Fc receptor cooperation. J Immunol. 2005; 174: 3041–3050. https://doi.org/10.4049/jimmunol.174.5.3041 PMID: 15728518

25. Ender F, Wiese AV, Schmudde T, Sun J, Vollbrandt T, König P, et al. Differential expression of C5a receptor 1 in innate immune cells during the allergic effector phase. PLoS ONE. 2017; 12: e0172446. https://doi.org/10.1371/journal.pone.0172446 PMID: 28231307

26. Krug N, Tschernig T, Erpenbeck VJ, Hofhild JM, Köhl J. Complement factors C3a and C5a are increased in bronchoalveolar lavage fluid after segmental allergen provocation in subjects with asthma. Am J Respir Crit Care Med. 2001; 164: 1841–1843. https://doi.org/10.1164/ajrccm.164.10.2010096 PMID: 11734433

27. Baelder R, Fuchs B, Bautsch W, Zwirmer J, Köhl J, Hoymann HG, et al. Pharmacological targeting of anaphylatoxin receptors during the effector phase of allergic asthma suppresses airway hyperresponsiveness and airway inflammation. J Immunol. 2005; 174: 783–789. https://doi.org/10.4049/jimmunol.174.2.783 PMID: 15634899

28. Khan MA, Nicolls MR, Surguladze B, Saadoun I. Complement components as potential therapeutic targets for asthma treatment. Respiratory Med. 2014; 108: 543–549. https://doi.org/10.1016/j.rmed.2014.01.005 PMID: 24468195

29. Zwirmer J, Fayyazi A, Götz O. Expression of the anaphylatoxin C5a receptor in non-myeloid cells. Mol Immunol. 1999; 36: 877–884. https://doi.org/10.1016/s0161-5890(99)00109-1 PMID: 10698342

30. Fayyazi A, Scheel O, Werfel T, Schwayer S, Oppermann M, Götz O, et al. The C5a receptor is expressed in normal renal proximal tubular but not in normal pulmonary or hepatic epithelial cells. Immunology. 2000; 99: 38–45. https://doi.org/10.1046/j.1365-2569.2000.00911.x PMID: 10651939

31. Schieferdecker HL, Schlaf G, Jungermann K, Götz O. Functions of anaphylatoxin C5a in rat liver: direct and indirect actions on nonparenchymal and parenchymal cells. Intern Immunopharmacol. 2001; 1: 469–481. https://doi.org/10.1016/s1567-5769(00)00038-2 PMID: 11367531

32. Schlaf G, Schmitz M, Rothermel E, Jungermann K, Schieferdecker HL, Götz O. Expression and induction of anaphylatoxin C5a receptors in the rat liver. Histol Histopathol. 2003; 18: 299–308. https://doi.org/10.14670/HH-18.299 PMID: 12507307
33. Daveau M, Benard M, Scotte M, Schouft MT, Hiron M, Francois A, et al. Expression of a functional complement receptor in regenerating hepatocytes and its involvement in a proliferative signalling pathway in rat. J Immunol. 2004; 173: 3418–3424. https://doi.org/10.4049/jimmunol.173.5.3418 PMID: 15322206

34. Atanes P, Ruiz-Maldonado I, Pingitore A, Hawkes R, Liu B, Zhao M, et al. C3aR and C5aR1 act as key regulators of human and mouse β-cell function. Cell Mol Life Sci. 2018; 75: 715–726. https://doi.org/10.1007/s00018-017-2655-1 PMID: 28921001

35. Pﬁeler J, Chung KJ, Chatzigeorgiou A, Klotzsche-von Ameln A, García-Martin R, Sprott D, et al. The complement anaphylatoxin C5a receptor contributes to obese adipose tissue inﬂammation and insulin resistance. J Immunol. 2013; 191: 4367–4374. https://doi.org/10.4049/jimmunol.1300038 PMID: 24043887

36. Zahedi R, Braun M, Wetsel RA, Ault BH, Khan A, Welch TR, et al. The C5a receptor is expressed by human renal proximal tubular epithelial cells. Clin Exp Immunol. 2000; 121: 226–233. https://doi.org/10.1046/j.1365-2249.2000.01249.x PMID: 10931135

37. Fayyazi A, Sandau R, Duong LQ, Götzte O, Radzun HJ, Schwery S, et al. C5a receptor and interleukin-6 are expressed in tissue macrophages and stimulated keratinocytes but not in pulmonary and intestinal epithelial cells. Am J Pathol. 1999; 154: 495–501. https://doi.org/10.1016/S0002-9440(10)65295-9 PMID: 10027407

38. Ma Y, Kong LR, Gu Q, Lu YY, Hong MN, Zhang Y, et al. Complement 5a-mediated trophoblasts dysfunction is involved in the development of pre-eclampsia. J Cell Mol Med. 2018; 22:1034–1046. https://doi.org/10.1111/jcmm.13466 PMID: 29168351

39. Girardi G, Yarilin D, Thurman JM, Holers VM, Salmon JE. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med. 2006; 203: 2165–2175. https://doi.org/10.1084/jem.20061022 PMID: 16923853

40. Banadakoppa M, Chauhan MS, Havemann D, Balakrishnan M, Dominic JS, Yallampalli C. Spontaneous abortion is associated with elevated systemic C5a and reduced mRNA of complement inhibitory proteins in placenta. Clin Exp Immunol. 2014; 177: 743–749. https://doi.org/10.1111/cei.12371 PMID: 24021013

41. Schraufstatter IU, DiScipio RG, Zhao M, Khaldoonyandi SK. C3a and C5a are chemotactic factors for human mesenchymal stem cells, which cause prolonged ERK1/2 phosphorylation. J Immunol. 2009; 182: 3827–3836. https://doi.org/10.4049/jimmunol.0803055 PMID: 19265162

42. Bújko K, Rzeszotek S, Hoehlig K, Yan J, Vater A, Ratajczak MZ. Signaling of the complement cleavage product anaphylatoxin C5a through C5aR (CD88) contributes to pharmacological hematopoietic stem cell mobilization. Stem Cell Rev and Rep. 2017; 13: 783–800. https://doi.org/10.1007/s12015-017-9769-6 PMID: 28918528

43. Gu J, Ding JY, Lu CL, Lin ZW, Chu YW, Zhao GY, et al. Overexpression of CDB8 predicts poor prognosis in non-small-cell lung cancer. Lung Cancer. 2013; 81: 259–265. https://doi.org/10.1016/j.lungcan.2013.04.020 PMID: 23706417

44. Ajona D, Zandueta C, Corrales L, Moreno H, Pajares MJ, Ortiz-Espinosa S, et al. Blockade of the complement C5a/C5aR1 axis impairs lung cancer bone metastasis by CXCL16-mediated effects. Am J Respir Crit Care Med. 2018; 197: 1164–1176. https://doi.org/10.1164/rccm.201703-0660OC PMID: 29327993

45. Zhao C, Li Y, Qiu W, He F, Zhang W, Zhao D, et al. C5a induces A549 cell proliferation of non-small cell lung cancer via GDF15 gene activation mediated by GCN5-dependent KLF5 acetylation. Oncogene. 2018; 37: 4821–4837. https://doi.org/10.1038/s41388-018-0298-9 PMID: 29773900

46. Imamura T, Yamamoto-Ibusuki M, Sueta A, Kubo T, Irie A, Kikuchi K, et al. Influence of the C5a-C5a receptor system on breast cancer progression and patient prognosis. Breast Cancer. 2016; 23: 876–885. https://doi.org/10.1007/s12282-015-0654-3 PMID: 26494574

47. Kaida T, Nitta H, Kitano Y, Yamamura K, Arima K, Izumi D, et al. C5a receptor in gastric cancer: implications for vascular invasion and patient outcomes. Med Oncol. 2016; 33: 118. https://doi.org/10.1007/s12032-016-0834-9 PMID: 27888239

48. Chen J, Li GQ, Zhang L, Tang M, Cao X, Xu GL, et al. Complement C5a/C5aR pathway potentiates the pathogenesis of gastric cancer by down-regulating p21 expression. Cancer Lett. 2018; 412: 30–36. https://doi.org/10.1016/j.canlet.2017.10.003 PMID: 29031586

49. Hu WH, Hu Z, Shen X, Dong LY, Zhou WZ, Yu XX. C5a receptor enhances hepatocellular carcinoma cell invasiveness via activating ERK1/2-mediated epithelial-mesenchymal transition. Exp Mol Pathol. 2016; 100: 101–108. https://doi.org/10.1016/j.yexmp.2015.10.001 PMID: 26475622
51. Maeda Y, Kawano Y, Wada Y, Yatsuda J, Motoshima T, Murakami Y, et al. C5aR is frequently expressed in metastatic renal cell carcinoma and plays a crucial role in cell invasion via the ERK and PI3 kinase pathways. Oncol Rep. 2015; 33: 1844–1850. https://doi.org/10.3892/or.2015.3800 PMID: 25682807

52. Yoneda M, Imamura R, Nitta H, Taniguchi K, Saito F, Kikuchi K, et al. Enhancement of cancer invasion and growth via the C5a-C5a receptor system: Implications for cancer promotion by autoimmune diseases and association with cervical cancer invasion. Oncol Lett. 2019; 17: 913–920. https://doi.org/10.3892/ol.2018.9715 PMID: 30655847

53. Cho MS, Vasquez HG, Rupaimoole R, Pradeep S, Wu S, Zand B, et al. Autocrine effects of tumor-derived complement. Cell Rep. 2014; 6: 1085–1095. https://doi.org/10.1016/j.celrep.2014.02.014 PMID: 24613353

54. Nunez-Cruz S, Gimotty PA, Guerra MW, Connolly DC, Wu YQ, DeAngelis RA, et al. Genetic and pharmacologic inhibition of complement inhibits endothelial cell function and ablates ovarian cancer neovascularization. Neoplasia. 2012; 14: 994–1004. https://doi.org/10.1593/neo.121262 PMID: 23226093